Key PointsQuestionWhat are the long-term outcomes after autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis? FindingsIn this multicenter cohort study of 281 patients with predominantly progressive forms of multiple sclerosis who underwent autologous hematopoietic stem cell transplant between 1995 and 2006, transplant-related mortality was 2.8% within 100 days of transplant, and neurological progression-free survival was 46% at 5 years. Younger age, relapsing form of multiple sclerosis, fewer prior immunotherapies, and lower neurological disability score were significantly associated with better outcomes. MeaningThe results support the rationale for further randomized clinical trials of autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis.
JAMA Neurology – American Medical Association
Published: Apr 20, 2017